- Trials with a EudraCT protocol (34)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
34 result(s) found for: Road rash.
Displaying page 1 of 2.
EudraCT Number: 2012-003136-23 | Sponsor Protocol Number: CRO1990 | Start Date*: 2012-11-27 | ||||||||||||||||||||||||||||||||||||
Sponsor Name:Imperial College London | ||||||||||||||||||||||||||||||||||||||
Full Title: Lamotrigine And Borderline Personality Disorder: Investigating Long-Term Effectiveness | ||||||||||||||||||||||||||||||||||||||
Medical condition: Borderline Personality Disorder | ||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||||||||||||
Trial protocol: GB (Completed) | ||||||||||||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2015-004901-18 | Sponsor Protocol Number: LAM107844 | Start Date*: 2016-08-03 |
Sponsor Name:GlaxoSmithKline Research & Development | ||
Full Title: Clinical Evaluation of lamotrigine in Epilepsy | ||
Medical condition: Epilepsy | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | |
Trial protocol: Outside EU/EEA | ||
Trial results: View results |
EudraCT Number: 2020-004144-28 | Sponsor Protocol Number: CCTU0307 | Start Date*: 2020-10-23 |
Sponsor Name:Cambridge university Hosptials NHS Foundation Trust and University of Cambridge | ||
Full Title: PROphylaxis for paTiEnts at risk of COVID-19 infecTion | ||
Medical condition: | ||
Disease: | ||
Population Age: | Gender: | |
Trial protocol: GB (GB - no longer in EU/EEA) | ||
Trial results: (No results available) |
EudraCT Number: 2007-003649-34 | Sponsor Protocol Number: RRT001 | Start Date*: 2008-08-08 | |||||||||||
Sponsor Name:University Hospital of South Manchester NHS Foundation Trust | |||||||||||||
Full Title: RENAL RESCUE IMMUNOSUPPRESSION FOLLOWING HEART TRANSPLANTATION | |||||||||||||
Medical condition: Renal impairment following heart transplantation | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2007-005781-12 | Sponsor Protocol Number: A6631013 | Start Date*: 2008-03-12 | |||||||||||
Sponsor Name:Pfizer Limited, Ramsgate Road, Sandwich, Kent UK | |||||||||||||
Full Title: A FOUR WEEK, MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, PHASE 2A STUDY OF PH-797804 IN THE TREATMENT OF POST-HERPETIC NEURALGIA | |||||||||||||
Medical condition: Post-herpetic neuralgia (PHN) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) SE (Completed) ES (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2006-001343-55 | Sponsor Protocol Number: A6061030 | Start Date*: 2006-08-02 | |||||||||||
Sponsor Name:Pfizer, S.A. | |||||||||||||
Full Title: A PHASE 2B LONG-TERM, RANDOMIZED, OPEN-LABEL, SAFETY AND TOLERABILITY TRIAL COMPARING [S,S]-REBOXETINE (PNU-165442G) WITH ROUTINE CARE IN PATIENTS WITH POSTHERPETIC NEURALGIA (PHN). | |||||||||||||
Medical condition: Postherpetic neuralgia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Completed) SE (Prematurely Ended) GB (Completed) LT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-000276-23 | Sponsor Protocol Number: 201464 | Start Date*: 2016-12-06 | ||||||||||||||||
Sponsor Name:GlaxoSmithKline Research & Development Ltd | ||||||||||||||||||
Full Title: A multiple treatment session, open label phase 2 clinical study of GSK2398852 administered following and together with GSK2315698 in cohorts of patients with cardiac amyloidosis | ||||||||||||||||||
Medical condition: Systemic amyloidosis | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: GB (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2005-005555-17 | Sponsor Protocol Number: A6061021 | Start Date*: 2006-09-04 | |||||||||||
Sponsor Name:Pfizer AB | |||||||||||||
Full Title: [S,S]-REBOXETINE ADD-ON TRIAL: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTI-CENTER TRIAL OF [S,S]-REBOXETINE IN PATIENTS WITH POSTHERPETIC NEURALGIA (PHN) CONCOMITANTLY TREATED WITH PREGAB... | |||||||||||||
Medical condition: Postherpetic Neuralgia` | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Prematurely Ended) DE (Prematurely Ended) GB (Completed) ES (Completed) NL (Completed) CZ (Completed) IT (Prematurely Ended) AT (Prematurely Ended) LV (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-001747-69 | Sponsor Protocol Number: GEMII-1 | Start Date*: 2011-10-28 | |||||||||||
Sponsor Name:Monash University
[...]
1. Monash University
2. NHS Lothian |
|||||||||||||
Full Title: Combination gefitinib and methotrexate to treat ectopic pregnancies II | |||||||||||||
Medical condition: Ectopic pregnancy or pregnancy of unknown location. | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-003635-10 | Sponsor Protocol Number: 2814 | Start Date*: 2018-05-23 |
Sponsor Name:University of Bristol | ||
Full Title: Immediate oral, immediate topical or delayed oral antibiotics for acute otitis media with discharge (the Runny Ear STudy: REST) | ||
Medical condition: Acute Otitis Media with discharge | ||
Disease: | ||
Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2017-004495-60 | Sponsor Protocol Number: I4V-MC-JAHU | Start Date*: 2019-09-24 | |||||||||||
Sponsor Name:Eli Lilly and Company | |||||||||||||
Full Title: A Randomized, Double-Blind, Placebo-Controlled, Withdrawal, Safety and Efficacy Study of Oral Baricitinib in Patients from 1 Year to Less than 18 Years Old with Systemic Juvenile Idiopathic Arthrit... | |||||||||||||
Medical condition: Systemic Juvenile Idiopathic Arthritis (sJIA) | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Trial now transitioned) GB (GB - no longer in EU/EEA) DE (Prematurely Ended) AT (Trial now transitioned) BE (Trial now transitioned) CZ (Trial now transitioned) PL (Trial now transitioned) DK (Prematurely Ended) ES (Ongoing) IT (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-003936-19 | Sponsor Protocol Number: CLR_16_22 | Start Date*: 2017-03-20 |
Sponsor Name:SUN Pharmaceuticals Global FZE | ||
Full Title: A Randomized, Double-Blind, Placebo-Controlled Phase 2a Study to Evaluate the Efficacy and Safety of Tildrakizumab in Subjects with Active Ankylosing Spondylitis or Non-Radiographic Axial Spondyloa... | ||
Medical condition: Ankylosing spondylitis (AS) and Non-Radiographic Axial Spondyloarthritis (nr-axSpA) | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: HU (Prematurely Ended) ES (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2007-000344-26 | Sponsor Protocol Number: V211-012-00 | Start Date*: 2007-06-04 | |||||||||||
Sponsor Name:Merck & Co., Inc. | |||||||||||||
Full Title: A Phase III Double-Blind, Randomized Multicenter Study to Evaluate the Safety, Tolerability and Immunogenicity of ZOSTAVAX administered comcomitantly versus Non-concomitantly with PNEUMOVAX 23 in s... | |||||||||||||
Medical condition: herpes zoster, pneumococcal infection | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) IT (Completed) GB (Completed) ES (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-000977-29 | Sponsor Protocol Number: EMA401-003 | Start Date*: 2011-07-12 | |||||||||||
Sponsor Name:Spinifex Pharmaceuticals Pty Ltd | |||||||||||||
Full Title: A double-blind, placebo-controlled, randomised trial to prove the therapeutic concept and to determine the safety, tolerability and pharmacokinetic profile of EMA401 (angiotensin II type 2 receptor... | |||||||||||||
Medical condition: postherpetic neuralgia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Completed) BG (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-003868-42 | Sponsor Protocol Number: R123899 | Start Date*: 2020-05-19 | |||||||||||
Sponsor Name:University of Manchester | |||||||||||||
Full Title: A randomised, phase IIa treatment delayed-start trial of the oral JAK 1/2 inhibitor, baricitinib, in the treatment of adult idiopathic inflammatory myopathy | |||||||||||||
Medical condition: Idiopathic Inflammatory Myopathy (IIM) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-002800-16 | Sponsor Protocol Number: C3591024 | Start Date*: 2019-12-10 | |||||||||||
Sponsor Name:Pfizer Inc. | |||||||||||||
Full Title: A PHASE 2A, 2-PART, OPEN-LABEL, NON-RANDOMIZED, MULTICENTER, SINGLE AND MULTIPLE DOSE TRIAL TO EVALUATE PHARMACOKINETICS, SAFETY AND TOLERABILITY OF CEFTAZIDIME AND AVIBACTAM IN NEONATES AND INFANT... | |||||||||||||
Medical condition: Infections with suspected or confirmed Gram-negative pathogens | |||||||||||||
|
|||||||||||||
Population Age: Preterm newborn infants, Newborns, Infants and toddlers, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: SK (Completed) HU (Completed) EE (Completed) GR (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-001211-24 | Sponsor Protocol Number: DRM06-AD07/J2T-DM-KGAA | Start Date*: Information not available in EudraCT | |||||||||||
Sponsor Name:Dermira, Inc., a wholly-owned subsidiary of Eli Lilly and Company | |||||||||||||
Full Title: A LONG-TERM STUDY TO ASSESS THE SAFETY AND EFFICACY OF LEBRIKIZUMAB IN PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS | |||||||||||||
Medical condition: Atopic dermatitis | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: PL (Completed) DE (Completed) LV (Completed) LT (Completed) EE (Completed) FR (Completed) BG (Completed) ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-002932-10 | Sponsor Protocol Number: DRM06-AD04 | Start Date*: 2020-03-06 | |||||||||||
Sponsor Name:Dermira, a wholly owned subsidiary of Eli Lilly and Company | |||||||||||||
Full Title: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF LEBRIKIZUMAB IN PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS | |||||||||||||
Medical condition: Atopic dermatitis | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: LT (Completed) ES (Completed) PL (Completed) EE (Completed) FR (Completed) LV (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-003591-37 | Sponsor Protocol Number: SPON846-10 | Start Date*: 2012-09-03 | |||||||||||
Sponsor Name:Cardiff University | |||||||||||||
Full Title: Children with Eczema Antibiotic Management Study (CREAM) | |||||||||||||
Medical condition: Atopic Eczema | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-001602-33 | Sponsor Protocol Number: RR15/114 | Start Date*: 2015-09-22 | |||||||||||
Sponsor Name:The University of Leeds | |||||||||||||
Full Title: A single arm, phase II open label trial to investigate the efficacy and safety of intra-dermal injection of etanercept for remission induction in discoid lupus erythematosus | |||||||||||||
Medical condition: Discoid lupus erythematosus | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
• EEA CTAs: Date study was authorised to proceed
• Outside EU/EEA: Date study was submitted in EudraCT
• Outside EU/EEA: Date study was submitted in EudraCT
